Media Appearances
‘A worst case scenario for Novo’: Read the market reaction to CagriSema trial
Novo Nordisk (NOVOb.CO), said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off the company’s value.
Kevin T. Gade, CFA, CFP®
Chief Operating Officer
Portfolio Manager & Principal
Continue to read the full article HERE with a feature from Kevin Gade.